Adoptive Cell Transfer (ACT) is a new type of immunotherapy that relies on boosting the ability of natural T cells to kill tumor cells. The aim of this study is to determine the effect of ACT and/or Sorafenib on colon cancer growth in vitro and on angiogenesis in vivo. HCT 116 and p53-/- cells were cultured in vitro and treated with different concentrations of either CD8 T cells isolated the PBMC of 2 healthy individuals or Sorafenib. The effect of both treatments on both cell lines was assessed using MTT. Colon cancer was induced using DMH injections in Balb/c. The mRNAs from the homogenized colonic tissues of chemotherapeutic and immunotherapeutic-treated mice were transcribed and quantified using RT-PCR. Results show that the IC50 of Sorafenib against HCT 116 and HCT 116 p53-/- cells was 50 and 35 µM, respectively. The IC50 of CD8 T cells in both cell lines was 10:1. In vivo, Sorafenib and/ or ACT significantly decreased the expressions of c-MYC (12-16 folds, p value <0.01), cyclin-D1 (18 folds, p value <0.001), PDGF-β (5-7 folds, p value <0.05), PDGF α (2-4 folds, p value <0.01) and β (3-6 folds, p value <0.001) receptors as compared to the untreated mice. Treatments significantly increased the expressions of CDC-4 by around 3 folds (p value <0.05) and non-significantly elevated the expressions of caspase-9 by 0.5 folds (p value >0.05) as compared to untreated mice. ACT can be used as a substituent or an adjunct to chemotherapy in colon cancer treatment.